Ákos Végvári

Ákos Végvári

Auto-generated profile, based on publicly available information

Ákos Végvári

Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Emerging Microbes & Infections
Verified
Journal Article
Open access
SASofia Appelberg
Sofia Appelberg
SGSoham Gupta
Soham Gupta
SASara Svensson Akusjärvi
Sara Svensson Akusjärvi
AAAnoop T. Ambikan
Anoop T. Ambikan
FMFlora Mikaeloff
Flora Mikaeloff
Ujjwal NeogiUjjwal Neogi
Ujjwal Neogi
How severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections engage cellular host pathways and innate immunity in infected cells remains largely elusive. We performed an integrative proteo-transcriptomics analysis in SARS-CoV-2 infected Huh7 cells to map the cellular response to the invading virus over time. We identified four pathways, ErbB, HIF-1, mTOR and TNF signaling, among others that were markedly modulated during the course of the SARS-CoV-2 infection in vitro. Western blot validation of the downstream effector molecules of these pathways revealed a dose-dependent activation of Akt, mTOR, S6K1 and 4E-BP1 at 24 hours post infection (hpi). However, we found a significant inhibition of HIF-1α through 24hpi and 48hpi of the infection, suggesting a crosstalk between the SARS-CoV-2 and the Akt/mTOR/HIF-1 signaling pathways. Inhibition of the mTOR signaling pathway using Akt inhibitor MK-2206 showed a significant reduction in virus production. Further investigations are required to better understand the molecular sequelae in order to guide potential therapy in the management of severe coronavirus disease 2019 (COVID-19) patients.

1 April 2010 in Journal of Proteomics
Verified
Journal Article
Closed access
JOJan Ottervald
Jan Ottervald
BFBo Franzén
Bo Franzén
KNKerstin Nilsson
Kerstin Nilsson
LALars I. Andersson
Lars I. Andersson
MKMohsen Khademi
Mohsen Khademi
TOTomas Olsson
Tomas Olsson

5 October 2021 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
SKShuba Krishnan
Shuba Krishnan
HNHampus Nordqvist
Hampus Nordqvist
AAAnoop T. Ambikan
Anoop T. Ambikan
SGSoham Gupta
Soham Gupta
MSMaike Sperk
Maike Sperk
Ujjwal NeogiUjjwal Neogi
Ujjwal Neogi
Viruses hijack host metabolic pathways for their replicative advantage. In this study, using patient-derived multiomics data and in vitro infection assays, we aimed to understand the role of key metabolic pathways that can regulate severe acute respiratory syndrome coronavirus-2 reproduction and their association with disease severity. We used multiomics platforms (targeted and untargeted proteomics and untargeted metabolomics) on patient samples and cell-line models along with immune phenotyping of metabolite transporters in patient blood cells to understand viral-induced metabolic modulations. We also modulated key metabolic pathways that were identified using multiomics data to regulate the viral reproduction in vitro. Coronavirus disease 2019 disease severity was characterized by increased plasma glucose and mannose levels. Immune phenotyping identified altered expression patterns of carbohydrate transporter, glucose transporter 1, in CD8+ T cells, intermediate and nonclassical monocytes, and amino acid transporter, xCT, in classical, intermediate, and nonclassical monocytes. In in vitro lung epithelial cell (Calu-3) infection model, we found that glycolysis and glutaminolysis are essential for virus replication, and blocking these metabolic pathways caused significant reduction in virus production. Taken together, we therefore hypothesized that severe acute respiratory syndrome coronavirus-2 utilizes and rewires pathways governing central carbon metabolism leading to the efflux of toxic metabolites and associated with disease severity. Thus, the host metabolic perturbation could be an attractive strategy to limit the viral replication and disease severity.

1 June 2011 in Journal of Proteomics
Verified
Journal Article
Closed access
GMGyörgy Marko-Varga
György Marko-Varga
TFThomas E. Fehniger
Thomas E. Fehniger
MRMelinda Rezeli
Melinda Rezeli
ÁGÁron Kristof Ghimessy
Áron Kristof Ghimessy
TLThomas Laurell
Thomas Laurell
ÁVÁkos Végvári
Ákos Végvári

1 November 2016 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
SCSilvia Pastoriza de la Cueva
Silvia Pastoriza de la Cueva
JÁJuana Álvarez
Juana Álvarez
ÁVÁkos Végvári
Ákos Végvári
JMJavier Montilla‐Gómez
Javier Montilla‐Gómez
OCOlga Cruz‐López
Olga Cruz‐López
José A. Rufián-HenaresJosé A. Rufián-Henares
José A. Rufián-Henares

16 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Amirata Saei DibavarAmirata Saei Dibavar
Amirata Saei Dibavar
CBChristian Michel Beusch
Christian Michel Beusch
ACAlexey Chernobrovkin
Alexey Chernobrovkin
PSPierre Sabatier
Pierre Sabatier
BZBo Zhang
Bo Zhang
JZJanet Zubarev
Janet Zubarev
Deconvolution of targets and action mechanisms of anticancer compounds is fundamental in drug development. Here, we report on ProTargetMiner as a publicly available expandable proteome signature library of anticancer molecules in cancer cell lines. Based on 287 A549 adenocarcinoma proteomes affected by 56 compounds, the main dataset contains 7,328 proteins and 1,307,859 refined protein-drug pairs. These proteomic signatures cluster by compound targets and action mechanisms. The targets and mechanistic proteins are deconvoluted by partial least square modeling, provided through the website http://protargetminer.genexplain.com. For 9 molecules representing the most diverse mechanisms and the common cancer cell lines MCF-7, RKO and A549, deep proteome datasets are obtained. Combining data from the three cell lines highlights common drug targets and cell-specific differences. The database can be easily extended and merged with new compound signatures. ProTargetMiner serves as a chemical proteomics resource for the cancer research community, and can become a valuable tool in drug discovery.